Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dade joins HF (heart failure) blood testing market in the US:

This article was originally published in Clinica

Executive Summary

Dade Behring has joined the growing rank of companies to have entered the emerging heart failure (HF) blood test market in the US. The Deerfield, Illinois firm has received FDA clearance to sell its cardiac marker assay NT-proBNP (N-terminal pro brain natriuretic peptide), which will be run on the company's Dimension instruments. Product shipments are anticipated to begin in the fourth quarter of this year. This is one quarter later than the original anticipated launch date due to antibody supply timing, the company said. Other firms to have gained approval to sell BNP-based HF tests are Biosite, Bayer Diagnostics, Roche Diagnostics, Axis-Shield and Abbott Laboratories.

Topics

UsernamePublicRestriction

Register

MT059197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel